caa a22 4500 445314192 CHVBK 20180317142640.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1007/s11095-010-0283-7 doi (NATIONALLICENCE)springer-10.1007/s11095-010-0283-7 Application of Alpha7 Nicotinic Acetylcholine Receptor Agonists in Inflammatory Diseases: An Overview [Elektronische Daten] [Mario Marrero, Merouane Bencherif, Patrick Lippiello, Rudolf Lucas] ABSTRACT: Inflammatory disorders are characterized by the influx of immune cells into the vascular wall of veins and/or arteries in response to stimuli such as oxidized-LDL and various pathogens. These factors stimulate the local production of pro-inflammatory cytokines by macrophages and other cells that promote various inflammatory diseases such as atherosclerosis, Crohn's, Alzheimer's and diabetes. Numerous cytokines play a significant role in this process, though tumor necrosis factor (TNF) and various interleukins are thought to be among the most important regulators. These proinflammatory cytokines promote the above-described diseases by inducing endothelial cell dysfunction. In this brief commentary we will discuss some of the latest advances and discoveries in the treatment of these inflammatory diseases, making use of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists. Springer Science+Business Media, LLC, 2010 inflammation nationallicence alpha7 nicotinic acetylcholine receptor agonists nationallicence cholinergic anti-inflammatory pathway nationallicence Jak/STAT pathway nationallicence Marrero Mario Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, USA aut Bencherif Merouane Preclinical Research, Targacept, Inc., Winston-Salem, North Carolina, USA aut Lippiello Patrick Preclinical Research, Targacept, Inc., Winston-Salem, North Carolina, USA aut Lucas Rudolf Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, USA aut Pharmaceutical Research Springer US; http://www.springer-ny.com 28/2(2011-02-01), 413-416 0724-8741 28:2<413 2011 28 11095 https://doi.org/10.1007/s11095-010-0283-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11095-010-0283-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Marrero Mario Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, USA aut NATIONALLICENCE 700 1- Bencherif Merouane Preclinical Research, Targacept, Inc., Winston-Salem, North Carolina, USA aut NATIONALLICENCE 700 1- Lippiello Patrick Preclinical Research, Targacept, Inc., Winston-Salem, North Carolina, USA aut NATIONALLICENCE 700 1- Lucas Rudolf Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, USA aut NATIONALLICENCE 773 0- Pharmaceutical Research Springer US; http://www.springer-ny.com 28/2(2011-02-01), 413-416 0724-8741 28:2<413 2011 28 11095 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer